Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson encourages investors who have lost more than $75,000 on Humacyte to contact him directly to discuss their options.
If you suffer a loss of more than $75,000 fumasite From May 10, 2024 to October 17, 2024 If you would like to discuss your legal rights, please call Faruqi and Faruqi Partners. josh wilson direct in 877-247-4292 or 212-983-9330 (extension 1310).
[You may also click here for additional information]
New York, New York–(Newsfile Corp. – January 5, 2025) – Faruqi & Faruqi, LLP, a leading national securities law firm, has announced a potential We are investigating the claim. (NASDAQ: HUMA), reminds investors. Deadline: January 17, 2025 Seeking to serve as lead plaintiff in a federal securities class action lawsuit filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California, and Georgia. The company has collected hundreds of millions of dollars from investors since its founding in 1995. Visit www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its officers violated federal securities laws by making false and/or misleading statements and/or failing to disclose: claims. Practices including quality assurance and microbiological testing. (2) FDA’s review of the BLA will be delayed while Humacyte corrects these deficiencies; (3) As a result, FDA approval of ATV for vascular trauma had significant risks. (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis;
On August 9, 2024, after the market closed, Humacyte issued a press release stating that the Food and Drug Administration (“FDA”) “has completed its review of its Biologics License Application (BLA) for acellular tissue modification products.” “This will require additional time.” Vascular Trauma Indications Vascular (ATEV). ” Part of this was revealed in the press release.[d]During the course of the BLA review, the FDA conducted inspections of our manufacturing facilities and clinical sites and has been actively involved in multiple discussions regarding our BLA submission.[.]”
Following this news, the company’s stock price fell $1.29 (16.4%) to close at $6.62 per share on August 12, 2024, due to unusual trading volume.
On October 17, 2024, during market hours, the FDA issued a Form 483 regarding Humacyte’s Durham, North Carolina facility, citing “lack of microbial quality assurance,” “lack of microbial testing,” and inadequate “quality oversight.” ” revealed a number of violations, including: . ”
Following this news, the company’s stock price fell $0.95 (16.35%) to close at $4.86 per share on October 17, 2024, due to unusual trading volume.
A court-appointed lead plaintiff is the investor with the greatest economic interest in the relief sought by the class and is an appropriate and typical class member to direct and oversee the litigation on behalf of the class. Any member of the putative class may petition the court to serve as lead plaintiff through an attorney of his or her choice, or may elect to take no action and remain an absent class member. . Your ability to participate in the recovery is not affected by your decision to become a lead plaintiff.
Faruqi & Faruqi, LLP also encourages anyone with information about Humacyte’s conduct, including whistleblowers, former employees and shareholders, to contact the company.
Follow us on LinkedIn, X, or Facebook (NASDAQ:) to stay up to date.
Lawyer advertisement. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Previous results do not guarantee or predict similar results with respect to future matters. We welcome the opportunity to discuss your specific case. All communications will be treated as confidential.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236011.
